Published in Blood Weekly, May 23rd, 2002
"Rituximab (chimeric anti-CD20) can reverse the cisplatin-resistant phenotype of AIDS-related non-Hodgkin's lymphoma cell lines and results in cisplatin-mediated apoptosis," explained Dr. Steve Alas and colleagues at the University of California Los Angeles School of Medicine and Jonsson Comprehensive Cancer Center.
The benefits of rituximab are mediated by its inhibition of the oncogene Bcl-2, Alas and coauthors found.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.